Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah J Colpitts

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Cancer Immunology, Immunotherapy : CII|April 15, 2023
Engineered murine IL-21-secreting leukemia cells induce granzyme B<sup>+</sup> T cells and CD4<sup>+</sup>CD44<sup>+</sup>CD62L<sup>-</sup> effector memory cells while suppressing regulatory T cells, leading to long-term survivalAlexandra Berger, Sarah J Colpitts, Morgan Zych, et al.
Diabetologia|September 22, 2021
Interactions between islets and regulatory immune cells in health and type 1 diabetesMatthew A Budd, Mahdis Monajemi, Sarah J Colpitts, et al.
Journal of Neurochemistry|January 17, 2020
Cellular models for discovering prion disease therapeutics: Progress and challengesSaffire H Krance, Russell Luke, Marc Shenouda, et al.
Frontiers in Immunology|March 20, 2023
Strategies for optimizing CITE-seq for human islets and other tissuesSarah J Colpitts, Matthew A Budd, Mahdis Monajemi, et al.
Journal for Immunotherapy of Cancer|December 21, 2019
Interleukin-15 in cancer immunotherapy: IL-15 receptor complex versus soluble IL-15 in a cancer cell-delivered murine leukemia modelAlexandra Berger, Sarah J Colpitts, Melanie S S Seabrook, et al.
Iscience|December 25, 2024
Single cell profiling of hematopoietic stem cell transplant recipients reveals TGF-β1 and IL-2 confer immunoregulatory functions to NK cellsJessica A Mathews, Dorota T Borovsky, Kyle T Reid, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 24, 2025
Cell therapy with human Interleukin 10-producing ILC2s enhances islet function and inhibits allograft rejectionSarah J Colpitts, Sinthuja Jegatheeswaran, Amanda Oakie, et al.
Cell Reports|December 25, 2024
Cell therapy with human IL-10-producing ILC2s limits xenogeneic graft-versus-host disease by inhibiting pathogenic T cell responsesKyle T Reid, Sarah J Colpitts, Jessica A Mathews, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Cancer Immunology, Immunotherapy : CII|April 15, 2023
Engineered murine IL-21-secreting leukemia cells induce granzyme B<sup>+</sup> T cells and CD4<sup>+</sup>CD44<sup>+</sup>CD62L<sup>-</sup> effector memory cells while suppressing regulatory T cells, leading to long-term survivalAlexandra Berger, Sarah J Colpitts, Morgan Zych, et al.
Diabetologia|September 22, 2021
Interactions between islets and regulatory immune cells in health and type 1 diabetesMatthew A Budd, Mahdis Monajemi, Sarah J Colpitts, et al.
Journal of Neurochemistry|January 17, 2020
Cellular models for discovering prion disease therapeutics: Progress and challengesSaffire H Krance, Russell Luke, Marc Shenouda, et al.
Frontiers in Immunology|March 20, 2023
Strategies for optimizing CITE-seq for human islets and other tissuesSarah J Colpitts, Matthew A Budd, Mahdis Monajemi, et al.
Journal for Immunotherapy of Cancer|December 21, 2019
Interleukin-15 in cancer immunotherapy: IL-15 receptor complex versus soluble IL-15 in a cancer cell-delivered murine leukemia modelAlexandra Berger, Sarah J Colpitts, Melanie S S Seabrook, et al.
Iscience|December 25, 2024
Single cell profiling of hematopoietic stem cell transplant recipients reveals TGF-β1 and IL-2 confer immunoregulatory functions to NK cellsJessica A Mathews, Dorota T Borovsky, Kyle T Reid, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 24, 2025
Cell therapy with human Interleukin 10-producing ILC2s enhances islet function and inhibits allograft rejectionSarah J Colpitts, Sinthuja Jegatheeswaran, Amanda Oakie, et al.
Cell Reports|December 25, 2024
Cell therapy with human IL-10-producing ILC2s limits xenogeneic graft-versus-host disease by inhibiting pathogenic T cell responsesKyle T Reid, Sarah J Colpitts, Jessica A Mathews, et al.
Pageof 1